CSL vs BBIO

Comparison between Carlisle Companies Inc (CSL, Company) and BridgeBio Pharma Inc (BBIO, Company).

CSL is from the Industrials sector, while BBIO is from the Healthcare sector.

5-Year PerformanceCSL has outperformed BBIO, delivering a return of +12.8% compared to +3.6%

CSL vs BBIO - Performance Comparison

Log

Key Characteristics

Financial metrics and valuation ratios

Metric	CSL(COMPANY)	BBIO(COMPANY)
Market Cap	$13B	$13B
Max Drawdown	65.48%	92.80%
Sharpe Ratio	-0.32	1.75
5Y Beta	1.00	1.08
Industry	Building Products & Equipment	Biotechnology
P/E Ratio	18.72	-18.09
Forward P/E	15.72	N/A
PEG Ratio	1.04	-3.23
Dividend Yield	1.31%	N/A
5Y Dividends CAGR	20.79%	N/A
5Y EPS CAGR	24.16%	-3.14%
Debt to Equity	174.73%	-116.44%
Free Cash Flow Yield	6.94%	-3.33%
P/S Ratio	2.67	23.04
P/B Ratio	7.97	123.68

Market Cap

CSL

$13B

Winner

BBIO

$13B

Max Drawdown

Winner

CSL

65.48%

BBIO

92.80%

Sharpe Ratio

CSL

-0.32

Winner

BBIO

1.75

5Y Beta

Winner

CSL

1.00

BBIO

1.08

Industry

CSL

Building Products & Equipment

BBIO

Biotechnology

P/E Ratio

CSL

18.72

Winner

BBIO

-18.09

Forward P/E

CSL

15.72

BBIO

N/A

PEG Ratio

CSL

1.04

Winner

BBIO

-3.23

Dividend Yield

CSL

1.31%

BBIO

N/A

5Y Dividends CAGR

CSL

20.79%

BBIO

N/A

5Y EPS CAGR

Winner

CSL

24.16%

BBIO

-3.14%

Debt to Equity

CSL

174.73%

Winner

BBIO

-116.44%

Free Cash Flow Yield

Winner

CSL

6.94%

BBIO

-3.33%

P/S Ratio

Winner

CSL

2.67

BBIO

23.04

P/B Ratio

Winner

CSL

7.97

BBIO

123.68

CSL vs BBIO - Historical Returns

Returns include dividend reinvestment.

Period	CSL	BBIO
1 month	-5.26%	-7.15%
3 months	-16.41%	+1.78%
6 months	+8.55%	+1.48%
1 year	-13.22%	+109.65%
5 years(CAGR)	+12.76%	+3.60%
10 years(CAGR)	+13.98%	N/A
Max(CAGR)	+13.73%	+14.26%

Winner

CSL

-5.26%

BBIO

-7.15%

CSL

-16.41%

Winner

BBIO

+1.78%

Winner

CSL

+8.55%

BBIO

+1.48%

CSL

-13.22%

Winner

BBIO

+109.65%

5Y(CAGR)

Winner

CSL

+12.76%

BBIO

+3.60%

10Y(CAGR)

CSL

+13.98%

BBIO

N/A

Max(CAGR)

CSL

+13.73%

Winner

BBIO

+14.26%

CSL vs BBIO - Annual Returns (1999 - 2026)

Returns include dividend reinvestment.

Year	CSL	BBIO
2026	+2.23%	-11.65%
2025	-11.66%	+171.24%
2024	+20.08%	-32.16%
2023	+35.04%	+463.04%
2022	-3.01%	-55.59%
2021	+62.98%	-73.79%
2020	-3.31%	+114.06%
2019	+62.36%	+27.22%
2018	-12.87%	N/A
2017	+5.48%	N/A
2016	+29.32%	N/A
2015	-0.33%	N/A
2014	+16.22%	N/A
2013	+32.88%	N/A
2012	+30.90%	N/A
2011	+11.21%	N/A
2010	+15.36%	N/A
2009	+64.68%	N/A
2008	-43.52%	N/A
2007	-5.44%	N/A
2006	+13.24%	N/A
2005	+10.86%	N/A
2004	+8.11%	N/A
2003	+44.81%	N/A
2002	+17.03%	N/A
2001	-9.48%	N/A
2000	+26.79%	N/A
1999	+10.53%	N/A

CSL vs BBIO Drawdown Comparison

The maximum drawdown for CSL was -64.55%, occurring on Nov 20, 2008. Recovery took 918 trading sessions.

The maximum drawdown for BBIO was -92.80%, occurring on May 11, 2022. Recovery took 1211 trading sessions.

The current CSL drawdown is -29.20%. The current BBIO drawdown is -13.50%.

Rank	CSL	BBIO
#1	-64.55% Sep 4, 2007 - Apr 26, 2011	-92.80% Feb 8, 2021 - Dec 3, 2025
#2	-45.55% Jun 29, 2000 - Oct 8, 2003	-65.45% Dec 23, 2019 - Nov 24, 2020
#3	-39.12% May 10, 2011 - Feb 21, 2012	-44.53% Sep 3, 2019 - Nov 20, 2019
#4	-38.68% Jan 2, 2020 - Mar 25, 2021	-21.99% Dec 31, 2020 - Feb 8, 2021
#5	-37.71% Oct 14, 2024 - Nov 20, 2025	-20.25% Jan 22, 2026 - Feb 5, 2026
#6	-34.51% Aug 18, 2022 - Dec 15, 2023	-16.79% Nov 22, 2019 - Dec 9, 2019
#7	-27.39% Aug 29, 2018 - Apr 18, 2019	-14.67% Jul 22, 2019 - Aug 26, 2019
#8	-25.34% Aug 17, 2015 - Apr 27, 2016	-12.87% Jul 11, 2019 - Jul 22, 2019
#9	-19.70% May 18, 2005 - Feb 9, 2006	-6.70% Dec 12, 2019 - Dec 18, 2019
#10	-19.47% Nov 25, 2016 - Nov 29, 2017	-6.15% Jan 2, 2026 - Jan 13, 2026
#11	-17.69% Jan 8, 2018 - Jul 25, 2018	-5.62% Jul 5, 2019 - Jul 11, 2019
#12	-15.01% May 4, 2022 - Jul 28, 2022	-5.28% Aug 27, 2019 - Sep 3, 2019
#13	-14.86% Jun 10, 2014 - Oct 30, 2014	-4.46% Dec 1, 2020 - Dec 4, 2020
#14	-14.45% Jul 16, 2024 - Sep 23, 2024	-4.45% Dec 18, 2019 - Dec 20, 2019
#15	-13.99% Jul 16, 2004 - Feb 3, 2005	-4.13% Dec 4, 2025 - Dec 12, 2025